

# ROAT




## **Croatian Agency for Medicinal Products and Medical**

**Devices (ALMP)** 

Decision on authorization and registration Quality, safety, efficacy - Croatian medicines Act and associated ordinances ALMP is also in charge of pharmacovigilance





HZZO

#### External price referencing and internal price referencing

- Original breakthrough products: up to 100% of the average price in Italy, France and Slovenia.
  Original me- too products: up to 90% of the price of equivalent products in Croatia
  Generic products: up to 70% of the average price in Italy, France and Slovenia and/or up to
- 90% of the price of the last bioequivalent generic introduced to the list.

### Pharmacy

instead.

No mark up for HZZO reimbursed medicines Service charge paid for dispensing

#### **Hospital pharmacy**

Price negotiations or tendering; HZZO reimburses as listed

- 2009/2010 REFORM
- Pharmaceutical expenditure on the decline 3<sup>rd</sup> year in a row 1.
- 85 innovative products listed from July 2009 to July 2011 (45 in total from 2002 to 2009) 2.
- 3. Pay back and cross product agreements introduced for innovative medicines
- 4. ISPOR aligned criteria for Budget Impact Analysis introduced
- 5. Reimbursement process made public on HZZO's web site
- 6. ePrescriptions introduced nationwide by January 2011
- 7. Ethical promotion agreement introduced with substantial penalties in place
- 8. Mandatory personalized reporting of all pharma expenditure on publicly employed